Bridge Therapy may Benefit Childhood Cancer Arising from Nerves

Neuroblastoma can often be cured by surgical removal of tumors followed by chemotherapy. These patients often receive induction therapy composed of various chemotherapy drugs and surgery, followed by consolidation therapy (given to kill any cancer cells that may be left in the body) involving high-dose chemotherapy plus stem cell transplants.

To examine the benefits of a bridge therapy strategy for patients with high-risk neuroblastoma whose cancer was still evident after induction therapy, researchers examined data from 201 patients diagnosed at various hospitals from 2008-to 2018 with neuroblastoma who had residual disease after completing induction therapy.

Patients were treated in three groups with different approaches based on physician, institutional, or family preferences. The first group is no bridging therapy before consolidation therapy, the second group is bridge therapy before consolidation therapy, and the third group comprises additional post-induction therapy without consolidation therapy.

The investigators were especially interested in evaluating if the addition of bridge therapy before consolidation with stem cell transplant improved the event-free survival or the time after treatment that cancer did not come back or get worse in patients with residual neuroblastoma at the end of induction therapy.

How Beneficial Was Bridging Therapy?

Patients who directly underwent consolidation (group 1) had better responses to induction therapy than patients who received bridge therapy before consolidation (group 2).

Event-free survival was similar in these two groups, however, suggesting that the addition of bridge therapy before consolidation therapy may benefit patients with a poor response to induction therapy.

Among patients with stable cancer at metastatic sites after induction therapy, those who received bridge therapy (group 2) had significantly improved event-free survival compared with those who directly underwent consolidation therapy (group 1).

Patients treated with post-induction therapy who did not receive consolidation therapy (group 3) experienced inferior event-free survival than patients in groups 1 or 2.

However, those in group 3 with no signs of metastatic cancer following post-induction therapy had significantly better 3-year event-free survival than those with residual metastatic disease.

Prospective studies are needed to confirm these findings and to help identify which patients may have long-term survival without consolidation with autologous stem cell transplant.

Source: Medindia